Silo Pharma Inc is a biotechnology company focused on leveraging psychedelic compounds and their therapeutic potential to treat various mental health conditions and neurological disorders
By researching and developing innovative drug delivery methods and formulations, the company aims to create effective treatments that can address unmet medical needs in the psychiatric space. Silo Pharma emphasizes collaboration with academic institutions and industry partners to advance its clinical programs and contribute to the evolving landscape of mental health therapies.
Silo Pharma (NASDAQSILO), a biopharmaceutical company developing novel therapeutics and drug delivery systems, announced that the U.S. Patent and Trademark Office (USPTO) has issued an Issue Notification for its patent application (No. 17/954,864), titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent, which is set to be issued on March 4, 2025, enhances protection for Silo’s lead asset, SPC-15, an intranasal treatment for PTSD. It expands on claims from a previous patent granted in November 2022 and reinforces the company’s intellectual property strategy as it moves toward clinical trials in collaboration with Columbia University.
SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025.
Silo Pharma (NASDAQSILO), a developmental-stage biopharmaceutical company, has filed a provisional patent application with the U.S. Patent and Trademark Office for its lead asset, SPC-15. The patent covers a dual-action method targeting stress-induced psychiatric behaviors through a combination of a serotonin type IV receptor agonist and an N-methyl-D-aspartate receptor antagonist. CEO Eric Weisblum emphasized the filing’s role in expanding the company’s intellectual property portfolio. SPC-15, originally licensed from Columbia University, is being developed as an intranasal treatment for PTSD and anxiety, with potential eligibility for the FDA’s 505(b)(2) regulatory pathway.
Silo Pharma (NASDAQSILO) announced encouraging early results from its ongoing study evaluating the pharmacokinetics, safety and tolerability of its SP-26 ketamine extended-release implant for chronic pain and fibromyalgia. The non-GLP study, launched in December 2024, marks the first small animal testing of SP-26, with dosing completed in early January. No serious side effects or discomfort were observed, and final safety and pharmacokinetic reports are expected in March 2025. CEO Eric Weisblum stated that a successful outcome could support further development of SP-26 as a chronic pain treatment.
Silo Pharma (NASDAQSILO), a developmental-stage biopharmaceutical company, has filed a provisional patent application with the U.S. Patent and Trademark Office (“USPTO”) for its lead asset SPC-15, demonstrating its commitment to innovative treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (“PTSD”). The patent focuses on targeting N-methyl-D-aspartate receptors (“NMDARs”) and serotonin type IV receptors (“5-HT4Rs”) to address stress-related behaviors such as perseverative behavior and hyponeophagia. Licensed through a collaboration with Columbia University, SPC-15 is exclusively owned and globally controlled by Silo for development and commercialization. CEO Eric Weisblum stated that the filing underscores Silo’s robust intellectual property (“IP”) strategy and enhances its ability to deliver transformative therapies. SPC-15, an intranasal serotonin 5-HT4 receptor agonist, also holds promise for the U.S. Food and Drug Administration’s (“FDA”) expedited 505(b)(2) approval pathway, facilitating accelerated development for PTSD and anxiety treatment.
SARASOTA, FL, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This application, focused on its lead asset SPC-15, highlights Silo’s commitment to advancing treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (PTSD).
Silo Pharma Inc.'s stock (NASDAQSILO) is on the the rise Wednesday following the company's announcement that it has been awarded a U.S. patent for its PTSD treatment titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females."
Silo Pharma (NASDAQSILO) received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent supporting its lead asset, SPC-15, an intranasal treatment for PTSD. The patent, expected to be formally issued within 90 days, builds on Silo’s existing intellectual property and expands protection for SPC-15, a serotonin 5-HT4 receptor agonist designed for stress-induced disorders like PTSD and anxiety. Licensed exclusively from Columbia University, SPC-15 is in preclinical studies and may benefit from the FDA’s expedited 505(b)(2) regulatory pathway.
SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application 17/954,864 for “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” Following receipt of the Notice of Allowance, Silo filed the final issue paperwork, paid the issue fees, and expects formal issuance of the patent in the next 90 days
SARASOTA, FL, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” “we,” “us,” “our,” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today issued a letter to shareholders highlighting the Company’s progress and potential for its lead assets SPC-15 and SP-26 as treatments for mental health and chronic pain management, respectively. The letter, in its entirety, is reprinted below.
Silo Pharma (NASDAQSILO), a biopharmaceutical company developing innovative therapeutics, has initiated a pharmacokinetic (“PK”) and tolerability study for its dissolvable ketamine-based implant, SP-26, in collaboration with AmplifyBio. The study will evaluate SP-26, aimed at treating chronic pain and fibromyalgia, in a minipig model over three weeks, focusing on absorption, distribution, metabolism, and excretion (“ADME”). Silo CEO Eric Weisblum highlighted the progress made through earlier analytical and manufacturing tests, emphasizing this study as a key milestone. AmplifyBio expressed its commitment to supporting Silo in advancing SP-26’s safety evaluation.
Silo Pharma (NASDAQSILO) has entered into a collaboration with Kymanox to develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant designed to treat fibromyalgia and chronic pain. The partnership will begin with proof-of-concept design, followed by prototype and feasibility testing to optimize insertion depth. Silo CEO Eric Weisblum highlighted the progress in developing SP-26, which aims to provide sustained pain relief and could potentially become the first FDA-approved at-home ketamine-based therapeutic. Kymanox also serves as Silo’s regulatory partner for SPC-15, a treatment targeting stress-induced affective disorders such as PTSD.
Silo Pharma stock is rising after announcing a collaboration with Kymanox to develop a subcutaneous insertion device for its SP-26 chronic pain treatment.
Silo Pharma (NASDAQSILO) announced encouraging preclinical study results for SPC-15, a novel dual-target therapy combining a serotonin 5-HT4 receptor agonist and an NMDA receptor antagonist. The treatment demonstrated superior efficacy in reducing stress-induced behaviors in animal models compared to single-agent therapies, highlighting its potential for managing major depressive disorder and other severe stress-related conditions. CEO Eric Weisblum emphasized the promising implications of SPC-15 as an intranasal prophylactic treatment for PTSD, with plans for an IND submission to initiate human trials. Developed in collaboration with Columbia University, SPC-15 may qualify for the FDA’s expedited 505(b)(2) approval pathway.
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions
